Market Cap 7.67B
Revenue (ttm) 1.48B
Net Income (ttm) 241.66M
EPS (ttm) N/A
PE Ratio 48.44
Forward PE N/A
Profit Margin 16.37%
Debt to Equity Ratio 0.86
Volume 3,726,400
Avg Vol 2,157,604
Day's Range N/A - N/A
Shares Out 166.68M
Stochastic %K 85%
Beta 0.38
Analysts Strong Sell
Price Target $47.69

Company Profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders....

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 353 1 772 8000
Address:
Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland
Nomorelies
Nomorelies Jun. 24 at 2:37 PM
$INCY Sector rotation is ongoing! Love it! $LABU &$IBRX $VKTX $BBIO $ALKS
0 · Reply
Nomorelies
Nomorelies Jun. 23 at 10:27 PM
0 · Reply
Otus
Otus Jun. 23 at 7:27 PM
$ALKS nice combination of results and rotation. The momo crowd loving this at the moment. I’ll hold my block.
0 · Reply
Nomorelies
Nomorelies Jun. 23 at 12:03 PM
$ALKS $INCY Hold.
0 · Reply
HoHoHoHum
HoHoHoHum Jun. 22 at 7:09 PM
$AUPH big XBI move today and several commercial stage companies get valuation boost — other than AUPH, $RIGL $ALKS $TGTX $NKTR to name a few!
1 · Reply
Nomorelies
Nomorelies Jun. 22 at 4:20 PM
$IBRX My bios are mainly up today. Possibly some sector rotation. $LABU $BBIO $INCY $ALKS
0 · Reply
CosmicMiner
CosmicMiner Jun. 21 at 6:44 PM
Biotech ETF XBI is shifting into a powerful Stage 2 uptrend, backed by clear signs of institutional accumulation. Top underlying holdings include $TGTX, $TVTX, $ALKS, $TWST, and $RVMD. After years of macro underperformance, the biotech sector is structurally turning constructive again. Avoid chasing extended moves; instead, look for entries where the reward ratio resets at key support levels. Rotation remains the dominant driver.
0 · Reply
stoxx0007
stoxx0007 Jun. 21 at 10:17 AM
$ALKS Definitely holding strong and building momentum 💪
0 · Reply
justiceforb_85
justiceforb_85 Jun. 19 at 2:24 AM
$ALKS continues to show strength. Alixorexton with good data in narcolepsy type 2.
0 · Reply
Quantumup
Quantumup Jun. 18 at 12:38 PM
Needham⬆️ $ALKS-$54 from$50/reitd Buy/said: ALKS presented updated data from the VIBRANCE-2 study at the SLEEP conference (LINK) where the efficacy profile for alixorexton continued to demonstrate improvement through week 13 (OLE) on ESS. CNTA - $LLY $AXSM HRMY JAZZ TAK Needham added—We also saw improvement in exploratory endpoints of PROMIS-fatigue and BC-CCI supporting development in indications such as fatigue in MS and Parkinson's Disease. 18 mg emerged as the dose with the best overall profile, with no discontinuations, and AE rates for insomnia (13%) and polikeuria (46%), which are quite competitive in our view. Further, across all doses we saw significant reduction on AE % from the double-blind portion to the OL portion, similar to VIBRANCE-1. Based on these updates we increase the peak share in NT2 and raise the POS in narcolepsy, increasing our PT to $54.
0 · Reply
Latest News on ALKS
Alkermes price target raised to $61 from $54 at Needham

2026-06-24T12:35:40.000Z - 17 hours ago

Alkermes price target raised to $61 from $54 at Needham


Alkermes price target raised to $50 from $42 at TD Cowen

2026-06-22T12:08:43.000Z - 2 days ago

Alkermes price target raised to $50 from $42 at TD Cowen


Alkermes announces ODD for Alixorexton in the U.S., Europe

2026-06-15T11:20:05.000Z - 9 days ago

Alkermes announces ODD for Alixorexton in the U.S., Europe


Alkermes price target raised to $56 from $45 at RBC Capital

2026-06-09T12:08:43.000Z - 15 days ago

Alkermes price target raised to $56 from $45 at RBC Capital


Alkermes to present new data on Alixorexton, LUMRYZ

2026-06-04T11:11:06.000Z - 20 days ago

Alkermes to present new data on Alixorexton, LUMRYZ


Alkermes price target raised to $48 from $45 at Baird

2026-05-13T13:45:55.000Z - 6 weeks ago

Alkermes price target raised to $48 from $45 at Baird


Alkermes Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Alkermes Proxy statement: Proxy filing


Alkermes price target raised to $48 from $42 at UBS

2026-05-07T09:39:27.000Z - 6 weeks ago

Alkermes price target raised to $48 from $42 at UBS


Alkermes price target raised to $50 from $45 at Needham

2026-05-07T03:49:23.000Z - 7 weeks ago

Alkermes price target raised to $50 from $45 at Needham

CNTA LLY


Alkermes Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Alkermes Earnings Call Transcript: Q1 2026


Alkermes Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Alkermes Earnings release: Q1 2026


Alkermes Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Alkermes Slides: Q1 2026


Alkermes Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Alkermes Quarterly report: Q1 2026


Alkermes reports Q1 EPS (40c) vs 13c last year

2026-05-05T11:07:37.000Z - 7 weeks ago

Alkermes reports Q1 EPS (40c) vs 13c last year


Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B

2026-05-05T11:07:20.000Z - 7 weeks ago

Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B


Alkermes plc Reports First Quarter 2026 Financial Results

May 5, 2026, 7:00 AM EDT - 7 weeks ago

Alkermes plc Reports First Quarter 2026 Financial Results


Alkermes price target raised to $36 from $34 at BofA

2026-04-09T13:42:00.000Z - 2 months ago

Alkermes price target raised to $36 from $34 at BofA


Alkermes price target lowered to $44 from $45 at RBC Capital

2026-04-07T15:06:04.000Z - 2 months ago

Alkermes price target lowered to $44 from $45 at RBC Capital


Alkermes Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Alkermes Proxy statement: Proxy filing


Alkermes Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Alkermes Proxy statement: Proxy filing


Alkermes management to meet with Piper Sandler

2026-04-01T20:50:16.000Z - 3 months ago

Alkermes management to meet with Piper Sandler


Alkermes Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Alkermes Proxy statement: Proxy filing


Alkermes Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 8:30 AM EDT - 3 months ago

Alkermes Transcript: Stifel 2026 Virtual CNS Forum


Alkermes to Present at the Stifel 2026 Virtual CNS Forum

Mar 10, 2026, 4:00 PM EDT - 3 months ago

Alkermes to Present at the Stifel 2026 Virtual CNS Forum


Alkermes Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:00 AM EST - 4 months ago

Alkermes Earnings Call Transcript: Q4 2025


Alkermes Annual report: Q4 2025

Feb 25, 2026, 8:00 AM EST - 4 months ago

Alkermes Annual report: Q4 2025


Alkermes Earnings release: Q4 2025

Feb 25, 2026, 8:00 AM EST - 4 months ago

Alkermes Earnings release: Q4 2025


Alkermes Slides: Q4 2025

Feb 25, 2026, 8:00 AM EST - 4 months ago

Alkermes Slides: Q4 2025


Alkermes plc Announces CEO Succession Plan

Feb 25, 2026, 6:55 AM EST - 4 months ago

Alkermes plc Announces CEO Succession Plan


Alkermes Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 5 months ago

Alkermes Slides: 44th Annual J.P. Morgan Healthcare Conference


Alkermes to Participate in Two Upcoming Investor Conferences

Nov 25, 2025, 4:00 PM EST - 7 months ago

Alkermes to Participate in Two Upcoming Investor Conferences


Alkermes Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 11:30 AM EST - 7 months ago

Alkermes Transcript: Jefferies London Healthcare Conference 2025


Alkermes raises offer for Avadel after Lundbeck bid

Nov 19, 2025, 6:08 AM EST - 7 months ago

Alkermes raises offer for Avadel after Lundbeck bid

AVDL


Alkermes Response to Avadel Announcement

Nov 14, 2025, 7:45 AM EST - 7 months ago

Alkermes Response to Avadel Announcement


Avadel Receives Unsolicited Proposal from Lundbeck

Nov 14, 2025, 5:45 AM EST - 7 months ago

Avadel Receives Unsolicited Proposal from Lundbeck

AVDL


Alkermes Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 2:40 PM EST - 7 months ago

Alkermes Transcript: Stifel 2025 Healthcare Conference


Alkermes Transcript: Study Update

Nov 12, 2025, 8:30 AM EST - 8 months ago

Alkermes Transcript: Study Update


Alkermes Press release: Study Update

Nov 12, 2025, 8:30 AM EST - 8 months ago

Alkermes Press release: Study Update


Alkermes Slides: Study Update

Nov 12, 2025, 8:30 AM EST - 8 months ago

Alkermes Slides: Study Update


Alkermes' narcolepsy drug meets main goal in a mid-stage trial

Nov 12, 2025, 7:35 AM EST - 8 months ago

Alkermes' narcolepsy drug meets main goal in a mid-stage trial


FORM 8.1(a) & (b) (Opening Position Disclosure)

Nov 5, 2025, 9:00 AM EST - 8 months ago

FORM 8.1(a) & (b) (Opening Position Disclosure)


Alkermes Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Alkermes Earnings Call Transcript: Q3 2025


Alkermes Quarterly report: Q3 2025

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Alkermes Quarterly report: Q3 2025


Alkermes Earnings release: Q3 2025

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Alkermes Earnings release: Q3 2025


Alkermes Slides: Q3 2025

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Alkermes Slides: Q3 2025


Alkermes plc Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 7:00 AM EDT - 8 months ago

Alkermes plc Reports Third Quarter 2025 Financial Results


Alkermes Transcript: M&A Announcement

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Alkermes Transcript: M&A Announcement


Alkermes Press release: M&A Announcement

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Alkermes Press release: M&A Announcement


Alkermes Slides: M&A Announcement

Oct 22, 2025, 8:00 AM EDT - 8 months ago

Alkermes Slides: M&A Announcement


Alkermes to acquire Avadel for up to $2.1 billion

Oct 22, 2025, 7:11 AM EDT - 8 months ago

Alkermes to acquire Avadel for up to $2.1 billion

AVDL


Alkermes Appoints Joshua Reed as Chief Financial Officer

Sep 12, 2025, 9:00 AM EDT - 10 months ago

Alkermes Appoints Joshua Reed as Chief Financial Officer


Alkermes Transcript: AGM 2025

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Alkermes Transcript: AGM 2025


Alkermes Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Alkermes Earnings Call Transcript: Q2 2025


Alkermes Quarterly report: Q2 2025

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Alkermes Quarterly report: Q2 2025


Alkermes Earnings release: Q2 2025

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Alkermes Earnings release: Q2 2025


Alkermes Slides: Q2 2025

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Alkermes Slides: Q2 2025


Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 7:00 AM EDT - 11 months ago

Alkermes plc Reports Second Quarter 2025 Financial Results


Alkermes Slides: Corporate Presentation

May 13, 2025, 7:00 AM EDT - 1 year ago

Alkermes Slides: Corporate Presentation


Alkermes Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Alkermes Proxy statement: Proxy Filing


Alkermes Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Alkermes Earnings Call Transcript: Q1 2025


Alkermes Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Alkermes Quarterly report: Q1 2025


Alkermes Earnings release: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Alkermes Earnings release: Q1 2025


Alkermes Slides: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Alkermes Slides: Q1 2025


Alkermes plc Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 1 year ago

Alkermes plc Reports First Quarter 2025 Financial Results


Nomorelies
Nomorelies Jun. 24 at 2:37 PM
$INCY Sector rotation is ongoing! Love it! $LABU &$IBRX $VKTX $BBIO $ALKS
0 · Reply
Nomorelies
Nomorelies Jun. 23 at 10:27 PM
0 · Reply
Otus
Otus Jun. 23 at 7:27 PM
$ALKS nice combination of results and rotation. The momo crowd loving this at the moment. I’ll hold my block.
0 · Reply
Nomorelies
Nomorelies Jun. 23 at 12:03 PM
$ALKS $INCY Hold.
0 · Reply
HoHoHoHum
HoHoHoHum Jun. 22 at 7:09 PM
$AUPH big XBI move today and several commercial stage companies get valuation boost — other than AUPH, $RIGL $ALKS $TGTX $NKTR to name a few!
1 · Reply
Nomorelies
Nomorelies Jun. 22 at 4:20 PM
$IBRX My bios are mainly up today. Possibly some sector rotation. $LABU $BBIO $INCY $ALKS
0 · Reply
CosmicMiner
CosmicMiner Jun. 21 at 6:44 PM
Biotech ETF XBI is shifting into a powerful Stage 2 uptrend, backed by clear signs of institutional accumulation. Top underlying holdings include $TGTX, $TVTX, $ALKS, $TWST, and $RVMD. After years of macro underperformance, the biotech sector is structurally turning constructive again. Avoid chasing extended moves; instead, look for entries where the reward ratio resets at key support levels. Rotation remains the dominant driver.
0 · Reply
stoxx0007
stoxx0007 Jun. 21 at 10:17 AM
$ALKS Definitely holding strong and building momentum 💪
0 · Reply
justiceforb_85
justiceforb_85 Jun. 19 at 2:24 AM
$ALKS continues to show strength. Alixorexton with good data in narcolepsy type 2.
0 · Reply
Quantumup
Quantumup Jun. 18 at 12:38 PM
Needham⬆️ $ALKS-$54 from$50/reitd Buy/said: ALKS presented updated data from the VIBRANCE-2 study at the SLEEP conference (LINK) where the efficacy profile for alixorexton continued to demonstrate improvement through week 13 (OLE) on ESS. CNTA - $LLY $AXSM HRMY JAZZ TAK Needham added—We also saw improvement in exploratory endpoints of PROMIS-fatigue and BC-CCI supporting development in indications such as fatigue in MS and Parkinson's Disease. 18 mg emerged as the dose with the best overall profile, with no discontinuations, and AE rates for insomnia (13%) and polikeuria (46%), which are quite competitive in our view. Further, across all doses we saw significant reduction on AE % from the double-blind portion to the OL portion, similar to VIBRANCE-1. Based on these updates we increase the peak share in NT2 and raise the POS in narcolepsy, increasing our PT to $54.
0 · Reply
anachartanalyst
anachartanalyst Jun. 18 at 11:01 AM
$ALKS https://anachart.com/wp-content/uploads/2026/06/1781780468_soc-img.jpg
0 · Reply
MadStockAlerts1
MadStockAlerts1 Jun. 18 at 7:42 AM
$ALKS just hit a real catalyst. Vibrance-2 met both primary endpoints, alixorexton showed clear, meaningful gains in wakefulness and daytime sleepiness vs placebo in narcolepsy. Well tolerated, no serious adverse events. Chart already has moving averages stacked, uptrend intact 📈
0 · Reply
DonCorleone77
DonCorleone77 Jun. 18 at 12:19 AM
$RUM $AXTI $ALKS $NUE $STLD AFTER-HOURS MOVERS: Currently Higher: - Rumble Inc. (RUM) up 17.0% after expansion into AI business - AXT, Inc. (AXTI) up 2.0% after subsidiary Tongmei enters supply agreement with Casela - Alkermes plc (ALKS) up 2.1% after positive results from Phase 2 study of Alixorexton - Nucor Corporation (NUE) up 1.0% after Q2 pre-announcement Currently Lower: - Steel Dynamics (STLD) down 2.6% after Q2 pre-announcement
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 17 at 11:50 PM
0 · Reply
topstockalerts
topstockalerts Jun. 17 at 10:23 PM
Alkermes reported positive Phase 2 results for alixorexton in patients with narcolepsy type 2, with the Vibrance-2 trial meeting both primary endpoints. The investigational once-daily therapy showed statistically significant and clinically meaningful improvements in wakefulness and excessive daytime sleepiness versus placebo after eight weeks. Patients treated with alixorexton demonstrated notable gains in the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with higher doses delivering the strongest results. Improvements in wakefulness, fatigue, and cognition were sustained during the open-label extension period. The drug was generally well tolerated, with no treatment-related serious adverse events reported. Common side effects included frequent urination, insomnia, urinary urgency, dizziness, and headache. Alixorexton is also being developed for narcolepsy type 1 and idiopathic hypersomnia. $ALKS
0 · Reply
FibonacciTrader_
FibonacciTrader_ Jun. 16 at 2:18 PM
Notable flow showing a clear mix of defensive positioning + small-cap convexity + macro hedge exposure. $PG 155C (7/17) - $2.8M - defensive mega-cap upside continuation, steady institutional accumulation in safety names $ALKS 45C (8/21) - $1.38M -- biotech optionality ahead of catalyst window, longer-dated upside structure $WYFI 35C (7/17) - $760K - lower liquidity name, momentum/speculative positioning $SILJ 32C (7/17) - $487K - silver miners / metals beta, inflation + macro hedge exposure $BTBT 2C (11/20) - $380K - crypto-linked high beta positioning, asymmetric upside lottery-style flow Overall tape shows capital rotating across three lanes: defensive compounding ($PG), commodities hedge ($SILJ), and high-beta speculative leverage ($BTBT, $WYFI). NFA.
0 · Reply
QuietTrader
QuietTrader Jun. 15 at 4:12 PM
Picking up some $ALKS here on a rare intraday pullback. This stock has been pointing north as of late.
0 · Reply
MarketBeat
MarketBeat Jun. 10 at 6:09 PM
https://marketbeat.com/a/8705927/ $ALKS Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
0 · Reply
stoxx0007
stoxx0007 Jun. 9 at 6:08 PM
$ALKS Very strong action for ALKS recently 💪 👏
1 · Reply
Quantumup
Quantumup Jun. 9 at 12:57 PM
RBC Capital⬆️ $ALKS's to $56 (was $45), reiterated Outperform and said: Don't Sleep On The Pipeline: While Early, Orexins May Have Real Applicability Outside Sleep CNTA - $LLY HRMY JAZZ TAK $AXSM RBC Capital added—While the developmental focus for orexin agonists has focused on sleep indications, we think as lead programs in the space become increasingly derisked, and valuations begin to climb, more attention should be paid to pipeline opportunities. While there may be potential in at least 5 major disorders, we see the strongest support for ADHD and addiction, the former of which ALKS is pursuing with initial data in 4Q26. We think nearterm data catalysts for these programs can help investors reframe ALKS as a leader in the space, with real upside optionality (~30%) across a budding orexin franchise, underwriting the valuation despite the recent runup.
0 · Reply
justiceforb_85
justiceforb_85 Jun. 4 at 9:14 PM
$ALKS solid company. Alixorexton likely better tolerated than $TAK's orexin 2.
0 · Reply